Hematological findings and complications of COVID‐19 E Terpos, I Ntanasis‐Stathopoulos, I Elalamy, E Kastritis, TN Sergentanis, ... American journal of hematology 95 (7), 834-847, 2020 | 2192 | 2020 |
Editor's Choice–European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis SK Kakkos, M Gohel, N Baekgaard, R Bauersachs, S Bellmunt-Montoya, ... European Journal of Vascular and Endovascular Surgery 61 (1), 9-82, 2021 | 512 | 2021 |
Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines Z Zhai, C Li, Y Chen, G Gerotziafas, Z Zhang, J Wan, P Liu, I Elalamy, ... Thrombosis and haemostasis 120 (06), 937-948, 2020 | 431 | 2020 |
Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee … T Baglin, A Hillarp, A Tripodi, I Elalamy, H Buller, W Ageno Journal of Thrombosis and Haemostasis 11 (4), 756-760, 2013 | 331 | 2013 |
Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent JC Gris, I Quéré, F Monpeyrou, E Mercier, S Ripart-Neveu, ML Tailland, ... Thrombosis and haemostasis 81 (06), 891-899, 1999 | 302 | 1999 |
Prevention and treatment of venous thromboembolism--International Consensus Statement. AN Nicolaides, J Fareed, AK Kakkar, AJ Comerota, SZ Goldhaber, R Hull, ... International angiology: a journal of the International Union of Angiology …, 2013 | 289 | 2013 |
A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS–Cancer‐Associated thrombosis study GT Gerotziafas, A Taher, H Abdel‐Razeq, E AboElnazar, AC Spyropoulos, ... The Oncologist 22 (10), 1222-1231, 2017 | 237 | 2017 |
Disseminated intravascular coagulation: an update on pathogenesis, diagnosis, and therapeutic strategies C Papageorgiou, G Jourdi, E Adjambri, A Walborn, P Patel, J Fareed, ... Clinical and applied thrombosis/hemostasis 24 (9_suppl), 8S-28S, 2018 | 217 | 2018 |
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban GT Gerotziafas, I Elalamy, F Depasse, E Perzborn, MM Samama Journal of Thrombosis and Haemostasis 5 (4), 886-888, 2007 | 200 | 2007 |
Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European independent foundation in angiology … GT Gerotziafas, M Catalano, MP Colgan, Z Pecsvarady, JC Wautrecht, ... Thrombosis and haemostasis 120 (12), 1597-1628, 2020 | 195 | 2020 |
Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram … GT Gerotziafas, F Depasse, J Busson, L Leflem, I Elalamy, MM Samama Thrombosis journal 3, 1-11, 2005 | 184 | 2005 |
Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis V Dufrost, J Risse, T Reshetnyak, M Satybaldyeva, Y Du, XX Yan, S Salta, ... Autoimmunity reviews 17 (10), 1011-1021, 2018 | 180 | 2018 |
In vitro aspirin resistance detected by PFA‐100TM closure time: pivotal role of plasma von Willebrand factor T Chakroun, G Gerotziafas, F Robert, C Lecrubier, MM Samama, M Hatmi, ... British journal of haematology 124 (1), 80-85, 2004 | 165 | 2004 |
2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group P Debourdeau, DK Chahmi, G Le Gal, I Kriegel, E Desruennes, ... Annals of Oncology 20 (9), 1459-1471, 2009 | 146 | 2009 |
Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation I Kazes, I Elalamy, JD Sraer, M Hatmi, G Nguyen Blood, The Journal of the American Society of Hematology 96 (9), 3064-3069, 2000 | 137 | 2000 |
Effect of the anti‐factor Xa and anti‐factor IIa activities of low‐molecular‐weight heparins upon the phases of thrombin generation GT Gerotziafas, AD Petropoulou, E Verdy, MM Samama, I Elalamy Journal of Thrombosis and Haemostasis 5 (5), 955-962, 2007 | 136 | 2007 |
Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up W Qin, S Chen, Y Zhang, F Dong, Z Zhang, B Hu, Z Zhu, F Li, X Wang, ... European Respiratory Journal 58 (1), 2021 | 126 | 2021 |
Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia I Elalamy, C Lecrubier, F Potevin, M Abdelouahed, L Bara, JP Marie, ... Thrombosis and haemostasis 74 (11), 1384-1385, 1995 | 122 | 1995 |
Circulating platelet–leukocyte aggregates: A marker of microvascular injury in diabetic patients I Elalamy, T Chakroun, GT Gerotziafas, A Petropoulou, F Robert, ... Thrombosis research 121 (6), 843-848, 2008 | 115 | 2008 |
Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin B Tardy, T Lecompte, F Boelhen, B Tardy-Poncet, I Elalamy, P Morange, ... Blood 108 (5), 1492-1496, 2006 | 114 | 2006 |